Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Data do not support claimed benefit of combination over single treatment
| The first 150 words of the full text of this article appear below. |
EDITOR
Mogensen et al interpret their results as showing that the
combination of lisinopril plus candesartan was more effective than
either agent alone at lowering blood pressure and reducing the urinary
albumin:creatinine ratio over 24 weeks in patients with type 2 (non-insulin dependent) diabetes.1 They state, "our
results . . . support this new and potentially highly
beneficial therapeutic approach for the prevention of diabetic renal
and vascular disease."
The authors' interpretation of the renoprotective effect of the combination and its superiority in lowering blood pressure does not seem to be supported by the results. Several methodological issues in particular limit their interpretation.
Firstly, the authors state in the abstract that "the reduction in
urinary albumin:creatinine ratio with combination treatment . . . was greater than with either candesartan
. . . or lisinopril." Table 4, however, shows that
the difference in the albumin:creatinine ratio between lisinopril and
the combination was not significant (P>0.20); they did not show that
the combination